Review



pdgf  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems pdgf
    Pdgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 40 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/Human+PDGF+Antibody/pmc12623973-478-20-30
    Average 93 stars, based on 40 article reviews
    pdgf - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Purification:

    Article Title: System, device and method for high-throughput multi-plexed detection
    Article Snippet: .. TABLE 1 List of all antibodies used Primary antibody (vendor: clone) (catalog No.) Secondary antibody (vendor: clone) (catalog No.) Mouse Anti-Human IFN gamma (ebio: NIB42) (14-7318) Anti-Human IFN gamma Biotin (ebio: 4S.B3) (13-7319) Anti-Human TNF alpha Purified (ebio: MAb1) (14-7348) Anti-Human TNF alpha Biotin (ebio: MAb11) (13-7349) Rat Anti-Human IL-2 (ebio: MQ1-17H12) (14-7029) Rabbit Anti-Human IL-2 Biotin (ebio: Polyclonal) (13-7028) Mouse Anti-Human IL-4 (ebio: 8D4-8) (14-7049) Mouse Anti-Human IL-4 biotin (ebio: MP4-25D2) (13-7048) Anti-human IL-1b (ebio: CRM56) (16-7018) Mouse Anti-Human IL-1 beta Biotin (ebio: CRM57) (13-7016) Mouse Anti-Human TNF beta (ebio: 359-238-8) (14- Mouse Anti-Human TNF beta Biotin (ebio: 359-81-11) (13-7327) 7329) Mouse anti-human RANTES (R&D) (DY278) Goat anti-human RANTES (R&D) (DY278) Rat Anti-Human IL-6 (ebio: MQ2-13A5) (14-7068) Rat Anti-Human IL-6 biotin (ebio: MQ2-39C3) (13-7068) Rat Anti-Human IL-10 (ebio: JES3-9D7) (14-7108) Rat Anti-Human IL-10 biotin (ebio: JES3-12G8) (13-7109) Mouse Anti-Human IL-12 (ebio: B-T21 (BT21)) (14- Mouse Anti-Human IL-12 biotin (ebio: C8.6) (13-7129) 7128) Anti-Human GMCSF (BD) (555126) Anti-Human GMCSF biotin (BD) (555126) Mouse Anti-CCL2 (MCP-1) (ebio: 5D3-F7) (14-7099) Armenian Hamster Anti-CCL2 (MCP-1) Biotin (ebio: 2H5) (13- 7096) Mouse Anti human EGF (R&D) (DY236) Goat Anti human EGF Biotin (R&D) (DY236) Mouse Anti human FGF basic (R&D) (DY233) Mouse Anti human FGF basic Biotin (R&D) (DY233) Mouse Anti human HGF (R&D) (DY294) Goat Anti human HGF Biotin (R&D) (DY294) Mouse Anti human PDGF-AB (R&D) (DY222) Goat Anti human PDGF-AB Biotin (R&D) (DY222) Goat Anti human TGF-a Biotin (R&D) (DY239) Goat Anti human TGF-a Biotin (R&D) (DY239) Mouse Anti human VEGF (R&D) (DY293B) Goat Anti human VEGF Biotin (R&D) (DY293B) Mouse Anti human MIF (R&D) (DY289) Goat Anti human MIF Biotin (R&D) (DY289) Rat Anti-Human IL-5 (ebio: TRFK5) (14-7052) Rat Anti-Human IL-5 biotin (ebio: JES1-5A10) (13-7059) Mouse Anti-Human IL-13 (ebio: PVM13-1) (14-7139) Rabbit Anti-Human IL-13 biotin (ebio: Polyclonal) (13-7138) Fabrication of Sub-Nanoliter Microchamber Array Chips The mold for the sub-nanoliter microchamber array is a silicon master etched with DRIE method. .. It was also pre-treated with chlorotrimethylsilane (Aldrich) vapor overnight to facilitate PDMS release.

    Article Title: System, device and method for high-throughput multi-plexed detection
    Article Snippet: .. TABLE 1 List of all antibodies used Primary antibody (vendor: clone)(catalog No.) Secondary antibody (vendor: clone) (catalog No.) Mouse Anti-Human IFN gamma (ebio: NIB42)(14-7318) Anti-Human IFN gamma Biotin(ebio: 4S.B3)(13-7319) Anti-Human TNF alpha Purified(ebio: MAb1)(14-7348) Anti-Human TNF alpha Biotin(ebio: MAb11) (13-7349) Rat Anti-Human IL-2(ebio: MQ1-17H12)(14-7029) Rabbit Anti-Human IL-2 Biotin(ebio: Polyclonal) (13-7028) Mouse Anti-Human IL-4(ebio: 8D4-8) (14-7049) Mouse Anti-Human IL-4 biotin(ebio: MP4-25D2)(13-7048) Anti-human IL-1b(ebio: CRM56)(16-7018) Mouse Anti-Human IL-1 beta Biotin(ebio: CRM57)(13-7016) Mouse Anti-Human TNF beta(ebio: 359-238-8)(14- Mouse Anti-Human TNF beta Biotin(ebio: 359-81-11) (13-7327) 7329) Mouse anti-human RANTES(R&D) (DY278) Goat anti-human RANTES(R&D) (DY278) Rat Anti-Human IL-6(ebio: MQ2-13A5) (14-7068) Rat Anti-Human IL-6 biotin(ebio: MQ2-39C3)(13-7068) Rat Anti-Human IL-10(ebio: JES3-9D7)(14-7108) Rat Anti-Human IL-10 biotin(ebio: JES3-12G8)(13-7109) Mouse Anti-Human IL-12(ebio: B-T21 (BT21))(14- Mouse Anti-Human IL-12 biotin(ebio: C8.6)(13-7129) 7128) Anti-Human GMCSF(BD)(555126) Anti-Human GMCSF biotin(BD)(555126) Mouse Anti-CCL2 (MCP-1)(ebio: 5D3-F7)(14-7099) Armenian Hamster Anti-CCL2 (MCP-1) Biotin(ebio: 2H5)(13- 7096) Mouse Anti human EGF(R&D) (DY236) Goat Anti human EGF Biotin (R&D) (DY236) Mouse Anti human FGF basic(R&D) (DY233) Mouse Anti human FGF basic Biotin (R&D) (DY233) Mouse Anti human HGF (R&D) (DY294) Goat Anti human HGF Biotin (R&D) (DY294) Mouse Anti human PDGF-AB (R&D) (DY222) Goat Anti human PDGF-AB Biotin (R&D) (DY222) Goat Anti human TGF-a Biotin (R&D) (DY239) Goat Anti human TGF-a Biotin (R&D) (DY239) Mouse Anti human VEGF (R&D) (DY293B) Goat Anti human VEGF Biotin (R&D) (DY293B) Mouse Anti human MIF (R&D) (DY289) Goat Anti human MIF Biotin (R&D) (DY289) Rat Anti-Human IL-5(ebio: TRFK5)(14-7052) Rat Anti-Human IL-5 biotin(ebio: JES1-5A10)(13-7059) Mouse Anti-Human IL-13(ebio: PVM13-1)(14-7139) Rabbit Anti-Human IL-13 biotin(ebio: Polyclonal)(13-7138) Fabrication of Sub-Nanoliter Microchamber Array Chips The mold for the sub-nanoliter microchamber array is a silicon master etched with DRIE method. .. It was also pre-treated with chlorotrimethylsilane (Aldrich) vapor overnight to facilitate PDMS release.

    Cell Culture:

    Article Title: Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis
    Article Snippet: .. VSMCs were cultured in 6-well plates with or without human PDGF-AB (R&D Systems, 20 ng/mL) to stimulate VSMC migration [6], and HuMoSC supernatant at 10% or 25%. ..

    Article Title: Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis
    Article Snippet: .. VSMCs were cultured with fresh DMEM (10% FBS), with or without human PDGF-AB (R&D Systems, 20 ng/mL) to stimulate VSMC proliferation [6], HuMoSC supernatant at 10% or 25% and Dexamethasone at 0.5 μg/ml. .. After 2, 4 and 7 days of culture, cells were fixed and stained with 0.2% crystal violet (Sigma-Aldrich) in 20% methanol for 20 minutes.

    Migration:

    Article Title: Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis
    Article Snippet: .. VSMCs were cultured in 6-well plates with or without human PDGF-AB (R&D Systems, 20 ng/mL) to stimulate VSMC migration [6], and HuMoSC supernatant at 10% or 25%. ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Compositions comprising collagen and PRP for tissue regeneration
    Article Snippet: .. Concentrations of human PDGF-AB and TGF-beta were determined using the commercially available Quantikine ELISA kits (R&D Systems). ..

    Control:

    Article Title: Viral inactivated platelet extract, use and preparation thereof
    Article Snippet: .. As a standard control, a recombinant human PDGF-AB (R&D Systems; Cat. ..

    Recombinant:

    Article Title: Viral inactivated platelet extract, use and preparation thereof
    Article Snippet: .. As a standard control, a recombinant human PDGF-AB (R&D Systems; Cat. ..



    Similar Products

    91
    Bio-Techne corporation human pdgf-ab quantikine elisa kit
    Human Pdgf Ab Quantikine Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/Human+PDGF-AB+Quantikine+ELISA+Kit/custom%40dhd00c%4041304770
    Average 91 stars, based on 1 article reviews
    human pdgf-ab quantikine elisa kit - by Bioz Stars, 2026-10
    91/100 stars
      Buy from Supplier

    94
    RayBiotech inc platelet derived growth factor
    Platelet Derived Growth Factor, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/Human+PDGF-AB+ELISA/us12558405-215-4-17
    Average 94 stars, based on 1 article reviews
    platelet derived growth factor - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems pdgf
    Pdgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/Human+PDGF+Antibody/pmc12623973-478-20-30
    Average 93 stars, based on 1 article reviews
    pdgf - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems polyclonal human pdgf antibody
    Flow cytometry analysis of (A) total granulocytes, (B) basophils, (C) eosinophils, (D) neutrophils, and platelets in the peripheral blood of non-osteoporotic frail controls (CON-F; n=16), osteopenic frail individuals (OPE; n=16), and osteoporotic frail individuals (OPO; n=28 out of 38). Differences in immune cell subsets were assessed using a Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test vs. CON-F if data were normally distributed. Non-normal data were analyzed with a Kruskal-Wallis test and Dunn’s multiple comparison. § indicates incomplete immune cell subset data. (E) Sera screening of non-osteoporotic middle-aged controls (CON-M), non-osteoporotic healthy older controls (CON-H), CON-F, OPE, and OPO individuals using bead-based multiplex assays. Clustered expression levels are given as median Z-scores. Factors with significantly different expression levels or distinct trends with p<0.1 in OPE or OPO individuals vs. CON-M, CON-H, and CON-F include (G) sCD40L, (H) <t>PDGF-BB,</t> (I) OPN, and (J) SDF-1. Differences between serum factors were assessed using two-way ANOVAs with Dunnett’s post-test (p<0.05) vs. CON-H, CON-M, or CON-F. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown. (K) Spearman correlation of the significantly different cellular and serum factors in non-osteoporotic controls (CON: CON-M, CON-H, CON-F) and (L) in osteopenic and osteoporotic individuals (low BMD: OPE, OPO). (M) Differences between correlation coefficients of CON and low BMD were assessed using Fisher’s Z-test; * p<0.05, ** p<0.001, *** p<0.0001.
    Polyclonal Human Pdgf Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/Human+PDGF+Antibody/bio_rxiv__2025__10__25__684499-180-21-29
    Average 93 stars, based on 1 article reviews
    polyclonal human pdgf antibody - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human pdgf-ab
    Flow cytometry analysis of (A) total granulocytes, (B) basophils, (C) eosinophils, (D) neutrophils, and platelets in the peripheral blood of non-osteoporotic frail controls (CON-F; n=16), osteopenic frail individuals (OPE; n=16), and osteoporotic frail individuals (OPO; n=28 out of 38). Differences in immune cell subsets were assessed using a Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test vs. CON-F if data were normally distributed. Non-normal data were analyzed with a Kruskal-Wallis test and Dunn’s multiple comparison. § indicates incomplete immune cell subset data. (E) Sera screening of non-osteoporotic middle-aged controls (CON-M), non-osteoporotic healthy older controls (CON-H), CON-F, OPE, and OPO individuals using bead-based multiplex assays. Clustered expression levels are given as median Z-scores. Factors with significantly different expression levels or distinct trends with p<0.1 in OPE or OPO individuals vs. CON-M, CON-H, and CON-F include (G) sCD40L, (H) <t>PDGF-BB,</t> (I) OPN, and (J) SDF-1. Differences between serum factors were assessed using two-way ANOVAs with Dunnett’s post-test (p<0.05) vs. CON-H, CON-M, or CON-F. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown. (K) Spearman correlation of the significantly different cellular and serum factors in non-osteoporotic controls (CON: CON-M, CON-H, CON-F) and (L) in osteopenic and osteoporotic individuals (low BMD: OPE, OPO). (M) Differences between correlation coefficients of CON and low BMD were assessed using Fisher’s Z-test; * p<0.05, ** p<0.001, *** p<0.0001.
    Recombinant Human Pdgf Ab, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/platelet+derived+growth+factor/pmc12266719-79-39-43
    Average 90 stars, based on 1 article reviews
    recombinant human pdgf-ab - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    PeproTech human pdgf-ab
    Flow cytometry analysis of (A) total granulocytes, (B) basophils, (C) eosinophils, (D) neutrophils, and platelets in the peripheral blood of non-osteoporotic frail controls (CON-F; n=16), osteopenic frail individuals (OPE; n=16), and osteoporotic frail individuals (OPO; n=28 out of 38). Differences in immune cell subsets were assessed using a Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test vs. CON-F if data were normally distributed. Non-normal data were analyzed with a Kruskal-Wallis test and Dunn’s multiple comparison. § indicates incomplete immune cell subset data. (E) Sera screening of non-osteoporotic middle-aged controls (CON-M), non-osteoporotic healthy older controls (CON-H), CON-F, OPE, and OPO individuals using bead-based multiplex assays. Clustered expression levels are given as median Z-scores. Factors with significantly different expression levels or distinct trends with p<0.1 in OPE or OPO individuals vs. CON-M, CON-H, and CON-F include (G) sCD40L, (H) <t>PDGF-BB,</t> (I) OPN, and (J) SDF-1. Differences between serum factors were assessed using two-way ANOVAs with Dunnett’s post-test (p<0.05) vs. CON-H, CON-M, or CON-F. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown. (K) Spearman correlation of the significantly different cellular and serum factors in non-osteoporotic controls (CON: CON-M, CON-H, CON-F) and (L) in osteopenic and osteoporotic individuals (low BMD: OPE, OPO). (M) Differences between correlation coefficients of CON and low BMD were assessed using Fisher’s Z-test; * p<0.05, ** p<0.001, *** p<0.0001.
    Human Pdgf Ab, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/human+pdgf+aa/pmc12173603-21-0-3
    Average 90 stars, based on 1 article reviews
    human pdgf-ab - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec research grade human
    Flow cytometry analysis of (A) total granulocytes, (B) basophils, (C) eosinophils, (D) neutrophils, and platelets in the peripheral blood of non-osteoporotic frail controls (CON-F; n=16), osteopenic frail individuals (OPE; n=16), and osteoporotic frail individuals (OPO; n=28 out of 38). Differences in immune cell subsets were assessed using a Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test vs. CON-F if data were normally distributed. Non-normal data were analyzed with a Kruskal-Wallis test and Dunn’s multiple comparison. § indicates incomplete immune cell subset data. (E) Sera screening of non-osteoporotic middle-aged controls (CON-M), non-osteoporotic healthy older controls (CON-H), CON-F, OPE, and OPO individuals using bead-based multiplex assays. Clustered expression levels are given as median Z-scores. Factors with significantly different expression levels or distinct trends with p<0.1 in OPE or OPO individuals vs. CON-M, CON-H, and CON-F include (G) sCD40L, (H) <t>PDGF-BB,</t> (I) OPN, and (J) SDF-1. Differences between serum factors were assessed using two-way ANOVAs with Dunnett’s post-test (p<0.05) vs. CON-H, CON-M, or CON-F. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown. (K) Spearman correlation of the significantly different cellular and serum factors in non-osteoporotic controls (CON: CON-M, CON-H, CON-F) and (L) in osteopenic and osteoporotic individuals (low BMD: OPE, OPO). (M) Differences between correlation coefficients of CON and low BMD were assessed using Fisher’s Z-test; * p<0.05, ** p<0.001, *** p<0.0001.
    Research Grade Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/Human+PDGF-AB%2C+research+grade/pmc11965535-13-1-5
    Average 94 stars, based on 1 article reviews
    research grade human - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems pdgf ab
    Flow cytometry analysis of (A) total granulocytes, (B) basophils, (C) eosinophils, (D) neutrophils, and platelets in the peripheral blood of non-osteoporotic frail controls (CON-F; n=16), osteopenic frail individuals (OPE; n=16), and osteoporotic frail individuals (OPO; n=28 out of 38). Differences in immune cell subsets were assessed using a Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test vs. CON-F if data were normally distributed. Non-normal data were analyzed with a Kruskal-Wallis test and Dunn’s multiple comparison. § indicates incomplete immune cell subset data. (E) Sera screening of non-osteoporotic middle-aged controls (CON-M), non-osteoporotic healthy older controls (CON-H), CON-F, OPE, and OPO individuals using bead-based multiplex assays. Clustered expression levels are given as median Z-scores. Factors with significantly different expression levels or distinct trends with p<0.1 in OPE or OPO individuals vs. CON-M, CON-H, and CON-F include (G) sCD40L, (H) <t>PDGF-BB,</t> (I) OPN, and (J) SDF-1. Differences between serum factors were assessed using two-way ANOVAs with Dunnett’s post-test (p<0.05) vs. CON-H, CON-M, or CON-F. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown. (K) Spearman correlation of the significantly different cellular and serum factors in non-osteoporotic controls (CON: CON-M, CON-H, CON-F) and (L) in osteopenic and osteoporotic individuals (low BMD: OPE, OPO). (M) Differences between correlation coefficients of CON and low BMD were assessed using Fisher’s Z-test; * p<0.05, ** p<0.001, *** p<0.0001.
    Pdgf Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf+ab/Recombinant+Human+PDGF-AB+Protein%2C+CF/bio_rxiv__2025__02__27__640640-129-19-22
    Average 93 stars, based on 1 article reviews
    pdgf ab - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results


    Flow cytometry analysis of (A) total granulocytes, (B) basophils, (C) eosinophils, (D) neutrophils, and platelets in the peripheral blood of non-osteoporotic frail controls (CON-F; n=16), osteopenic frail individuals (OPE; n=16), and osteoporotic frail individuals (OPO; n=28 out of 38). Differences in immune cell subsets were assessed using a Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test vs. CON-F if data were normally distributed. Non-normal data were analyzed with a Kruskal-Wallis test and Dunn’s multiple comparison. § indicates incomplete immune cell subset data. (E) Sera screening of non-osteoporotic middle-aged controls (CON-M), non-osteoporotic healthy older controls (CON-H), CON-F, OPE, and OPO individuals using bead-based multiplex assays. Clustered expression levels are given as median Z-scores. Factors with significantly different expression levels or distinct trends with p<0.1 in OPE or OPO individuals vs. CON-M, CON-H, and CON-F include (G) sCD40L, (H) PDGF-BB, (I) OPN, and (J) SDF-1. Differences between serum factors were assessed using two-way ANOVAs with Dunnett’s post-test (p<0.05) vs. CON-H, CON-M, or CON-F. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown. (K) Spearman correlation of the significantly different cellular and serum factors in non-osteoporotic controls (CON: CON-M, CON-H, CON-F) and (L) in osteopenic and osteoporotic individuals (low BMD: OPE, OPO). (M) Differences between correlation coefficients of CON and low BMD were assessed using Fisher’s Z-test; * p<0.05, ** p<0.001, *** p<0.0001.

    Journal: bioRxiv

    Article Title: A complex osteoporotic milieu is associated with arterial stiffening and PDGF-BB-mediated calcification of human smooth muscle cells

    doi: 10.1101/2025.10.25.684499

    Figure Lengend Snippet: Flow cytometry analysis of (A) total granulocytes, (B) basophils, (C) eosinophils, (D) neutrophils, and platelets in the peripheral blood of non-osteoporotic frail controls (CON-F; n=16), osteopenic frail individuals (OPE; n=16), and osteoporotic frail individuals (OPO; n=28 out of 38). Differences in immune cell subsets were assessed using a Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test vs. CON-F if data were normally distributed. Non-normal data were analyzed with a Kruskal-Wallis test and Dunn’s multiple comparison. § indicates incomplete immune cell subset data. (E) Sera screening of non-osteoporotic middle-aged controls (CON-M), non-osteoporotic healthy older controls (CON-H), CON-F, OPE, and OPO individuals using bead-based multiplex assays. Clustered expression levels are given as median Z-scores. Factors with significantly different expression levels or distinct trends with p<0.1 in OPE or OPO individuals vs. CON-M, CON-H, and CON-F include (G) sCD40L, (H) PDGF-BB, (I) OPN, and (J) SDF-1. Differences between serum factors were assessed using two-way ANOVAs with Dunnett’s post-test (p<0.05) vs. CON-H, CON-M, or CON-F. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown. (K) Spearman correlation of the significantly different cellular and serum factors in non-osteoporotic controls (CON: CON-M, CON-H, CON-F) and (L) in osteopenic and osteoporotic individuals (low BMD: OPE, OPO). (M) Differences between correlation coefficients of CON and low BMD were assessed using Fisher’s Z-test; * p<0.05, ** p<0.001, *** p<0.0001.

    Article Snippet: The role of PDGF-BB was further assessed using osteogenic medium containing sex-mixed participant-derived sera pools supplemented with either 25 μg/ml neutralizing polyclonal human PDGF antibody (αPDGF; Cat# AB-20, RRID:AB_354273; R&D Systems ® ) dissolved in PBS, or 50 μM chebulinic acid (CheA; Cat# SMB00271, Sigma-Aldrich or Cat# A16208, AdooQ ® BioScience, USA), dissolved in ddH 2 O and briefly heated up to 70 °C to prepare a 1 mM stock.

    Techniques: Flow Cytometry, Comparison, Multiplex Assay, Expressing

    SMC undergoing osteogenic differentiation (OM - osteogenic medium) in an in vitro model of SMC calcification were stimulated with recombinant PDGF-BB, sCD40L, OPN, or SDF-1α. Deposited calcified matrix was stained with alizarin red. (A ) Representative images of the deposited calcified matrix. (B-E) Quantified staining, normalized to cell count. A paired, two-tailed t-test was used to assess significant differences (p<0.05) vs. OM without supplements for each time point. (F) Phosphate levels in the supernatant during osteogenic differentiation with the respective recombinant factors. Statistical analysis at each time point was performed using a mixed-effects model with Geisser-Greenhouse correction and Dunnett’s post-test vs. OM without supplements (p<0.05); no significant differences were detected. (G) SMC proliferation in expansion medium (EM; dashed line) after stimulation with the respective recombinant factors. Differences in proliferation were assessed at each time point using two-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test vs. EM without supplements (p<0.05); no significant differences were detected. (H) Gene expression analysis of SMC after four days of osteogenic differentiation with the respective recombinant factors. Paired, two-tailed t-tests vs. OM without supplements were used to assess significant differences (p<0.05) across independent experiments.

    Journal: bioRxiv

    Article Title: A complex osteoporotic milieu is associated with arterial stiffening and PDGF-BB-mediated calcification of human smooth muscle cells

    doi: 10.1101/2025.10.25.684499

    Figure Lengend Snippet: SMC undergoing osteogenic differentiation (OM - osteogenic medium) in an in vitro model of SMC calcification were stimulated with recombinant PDGF-BB, sCD40L, OPN, or SDF-1α. Deposited calcified matrix was stained with alizarin red. (A ) Representative images of the deposited calcified matrix. (B-E) Quantified staining, normalized to cell count. A paired, two-tailed t-test was used to assess significant differences (p<0.05) vs. OM without supplements for each time point. (F) Phosphate levels in the supernatant during osteogenic differentiation with the respective recombinant factors. Statistical analysis at each time point was performed using a mixed-effects model with Geisser-Greenhouse correction and Dunnett’s post-test vs. OM without supplements (p<0.05); no significant differences were detected. (G) SMC proliferation in expansion medium (EM; dashed line) after stimulation with the respective recombinant factors. Differences in proliferation were assessed at each time point using two-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test vs. EM without supplements (p<0.05); no significant differences were detected. (H) Gene expression analysis of SMC after four days of osteogenic differentiation with the respective recombinant factors. Paired, two-tailed t-tests vs. OM without supplements were used to assess significant differences (p<0.05) across independent experiments.

    Article Snippet: The role of PDGF-BB was further assessed using osteogenic medium containing sex-mixed participant-derived sera pools supplemented with either 25 μg/ml neutralizing polyclonal human PDGF antibody (αPDGF; Cat# AB-20, RRID:AB_354273; R&D Systems ® ) dissolved in PBS, or 50 μM chebulinic acid (CheA; Cat# SMB00271, Sigma-Aldrich or Cat# A16208, AdooQ ® BioScience, USA), dissolved in ddH 2 O and briefly heated up to 70 °C to prepare a 1 mM stock.

    Techniques: In Vitro, Recombinant, Staining, Cell Counting, Two Tailed Test, Gene Expression

    (A) SMC undergoing osteogenic differentiation were stimulated with sex-mixed sera pools of non-osteoporotic healthy older controls (CON-H) or osteoporotic frail individuals with (OPO + ) or without confounders of vascular calcification (OPO - ). PDGF-BB or its downstream signaling was inhibited in the respective sera pools using either 25 µg/ml neutralizing polyclonal PDGF antibody (αPDGF) or 50 µM chebulinic acid (CheA). Deposited calcified matrix was stained with alizarin red, quantified, and normalized to the cell count. A one-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test was used to assess significant differences vs. CON-H and the respective osteoporotic group without inhibitor for each time point. (B) Representative images of deposited calcified matrix stained with alizarin red. (C) Phosphate levels determined in the supernatant during osteogenic differentiation. A two-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test was used to assess significant differences vs. CON-H for each time point. (D) Cell counts determined by Hoechst staining after stimulation with the respective sera pools supplemented with αPDGF or CheA. A one-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test was used to assess significant differences vs. CON-H and the respective osteoporotic group without inhibitor for each time point. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown.

    Journal: bioRxiv

    Article Title: A complex osteoporotic milieu is associated with arterial stiffening and PDGF-BB-mediated calcification of human smooth muscle cells

    doi: 10.1101/2025.10.25.684499

    Figure Lengend Snippet: (A) SMC undergoing osteogenic differentiation were stimulated with sex-mixed sera pools of non-osteoporotic healthy older controls (CON-H) or osteoporotic frail individuals with (OPO + ) or without confounders of vascular calcification (OPO - ). PDGF-BB or its downstream signaling was inhibited in the respective sera pools using either 25 µg/ml neutralizing polyclonal PDGF antibody (αPDGF) or 50 µM chebulinic acid (CheA). Deposited calcified matrix was stained with alizarin red, quantified, and normalized to the cell count. A one-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test was used to assess significant differences vs. CON-H and the respective osteoporotic group without inhibitor for each time point. (B) Representative images of deposited calcified matrix stained with alizarin red. (C) Phosphate levels determined in the supernatant during osteogenic differentiation. A two-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test was used to assess significant differences vs. CON-H for each time point. (D) Cell counts determined by Hoechst staining after stimulation with the respective sera pools supplemented with αPDGF or CheA. A one-way ANOVA with Geisser-Greenhouse correction and Dunnett’s post-test was used to assess significant differences vs. CON-H and the respective osteoporotic group without inhibitor for each time point. Only significant differences (p<0.05) and distinct trends with p<0.1 are shown.

    Article Snippet: The role of PDGF-BB was further assessed using osteogenic medium containing sex-mixed participant-derived sera pools supplemented with either 25 μg/ml neutralizing polyclonal human PDGF antibody (αPDGF; Cat# AB-20, RRID:AB_354273; R&D Systems ® ) dissolved in PBS, or 50 μM chebulinic acid (CheA; Cat# SMB00271, Sigma-Aldrich or Cat# A16208, AdooQ ® BioScience, USA), dissolved in ddH 2 O and briefly heated up to 70 °C to prepare a 1 mM stock.

    Techniques: Staining, Cell Counting